SCHEMBL30451083

SCHEMBL30451083

COc1cccc([C@@](O)(C(=O)O)C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
PTPN1 P18031 1/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
LMNA P02545 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
NR1H2 P55055 1/20 0.43
PARP1 P09874 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18921671 1.00 PDK1 (0.49) PDK1PDK2PDK3PDK4PTPN1
SCHEMBL18921672 1.00 PDK1 (0.49) PDK1PDK2PDK3PDK4PTPN1
SCHEMBL20072129 0.86 PARP1 (0.49) PDK1PDK2PDK3PDK4CES2
SCHEMBL18921632 0.84 CETP (0.48) PTPN1KIF11
SCHEMBL18921633 0.84 CETP (0.48) PTPN1KIF11
SCHEMBL20072035 0.84 PDK1 (0.52) PDK1PDK2PDK3PDK4CES2
SCHEMBL20073974 0.84 PDK1 (0.52) PDK1PDK2PDK3PDK4CES2
SCHEMBL20074079 0.84 PDK1 (0.46) PDK1PDK2PDK3PDK4CES2
SCHEMBL22285693 0.82 CES2 (0.49) PDK1PDK2PDK3PDK4CES2
SCHEMBL31256902 0.82 CES2 (0.49) PDK1PDK2PDK3PDK4CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 EP disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 PDK1 2497/4885PDK2 2381/4885PDK3 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.